Kunz Meik, Göttlich Claudia, Walles Thorsten, Nietzer Sarah, Dandekar Gudrun, Dandekar Thomas
1 Functional Genomics and Systems Biology Group, Department of Bioinformatics, Biocenter, Würzburg, Germany.
2 Department of Tissue Engineering and Regenerative Medicine (TERM), University Hospital Würzburg, Würzburg, Germany.
Tumour Biol. 2017 Jul;39(7):1010428317706430. doi: 10.1177/1010428317706430.
MicroRNAs are well-known strong RNA regulators modulating whole functional units in complex signaling networks. Regarding clinical application, they have potential as biomarkers for prognosis, diagnosis, and therapy. In this review, we focus on two microRNAs centrally involved in lung cancer progression. MicroRNA-21 promotes and microRNA-34 inhibits cancer progression. We elucidate here involved pathways and imbed these antagonistic microRNAs in a network of interactions, stressing their cancer microRNA biology, followed by experimental and bioinformatics analysis of such microRNAs and their targets. This background is then illuminated from a clinical perspective on microRNA-21 and microRNA-34 as general examples for the complex microRNA biology in lung cancer and its diagnostic value. Moreover, we discuss the immense potential that microRNAs such as microRNA-21 and microRNA-34 imply by their broad regulatory effects. These should be explored for novel therapeutic strategies in the clinic.
微小RNA是众所周知的强大RNA调节因子，可在复杂的信号网络中调节整个功能单元。就临床应用而言，它们有潜力作为预后、诊断和治疗的生物标志物。在本综述中，我们聚焦于两个在肺癌进展中起核心作用的微小RNA。微小RNA-21促进癌症进展，而微小RNA-34抑制癌症进展。我们在此阐明相关途径，并将这些拮抗性微小RNA嵌入相互作用网络中，强调它们的癌症微小RNA生物学特性，随后对这类微小RNA及其靶标进行实验和生物信息学分析。然后从临床角度，以微小RNA-21和微小RNA-34为例，阐明肺癌复杂微小RNA生物学及其诊断价值的背景。此外，我们讨论了微小RNA-21和微小RNA-34等微小RNA因其广泛的调节作用所蕴含的巨大潜力。临床应探索这些潜力以开发新的治疗策略。
